Ideaya wraps $50M IPO to fu­el clin­i­cal dri­ve on syn­thet­ic lethal­i­ty

Ideaya Bio­sciences has fol­lowed sev­er­al oth­er down­sized IPOs on­to the Nas­daq, be­gin­ning a new pub­lic life with a $50 mil­lion raise and the tick­er sym­bol $IDYA.

Led by CEO Yu­jiro Ha­ta, an ex­pe­ri­enced biotech ex­ec who built the South San Fran­cis­co com­pa­ny from scratch while an en­tre­pre­neur-in-res­i­dence at 5AM, Ideaya is all about tar­get­ed can­cer ther­a­pies and syn­thet­ic lethal­i­ty — the strat­e­gy of tar­get­ing two genes si­mul­ta­ne­ous­ly for a more po­tent ef­fect. It’s start­ing out with an ear­ly-stage drug picked up for a song from No­var­tis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.